Stock Ratings / Health Care / LIVN / insiders

ITGR (67) AXGN (54) TMDX (69) CNMD (62) ⌘ Pro Terminal →

LivaNova PLC (LIVN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$81.25 +0.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $81.20

LivaNova PLC (LIVN) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $4.48B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LIVN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LIVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, LivaNova PLC (NASDAQ: LIVN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $81.25 (+0.73% 1D, market cap $4.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, LIVN ranks #179 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LIVN compare to ITGR and AXGN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), LIVN carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of 17.3%. By comparison, ITGR (Integer Holdings Corporation) holds a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B) and AXGN (Axogen Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -2.6%, cap $2.96B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LIVN?

▼

Per LIVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001639691), LivaNova PLC generated $1.39B in revenue (+10.7% YoY), -$242.5M in net income, and $173.3M in free cash flow against $2.61B in total assets and $345.2M in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $81.20 (-0.06%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 12.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LIVN)Realized 20D OHLCV Swing Band: ±6.1%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY LIVN SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 12.5% FCF Margin ($173.3M FCF) & 67.7% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (20% of score)

Altman Z-Score 2.21 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$76.39+1.6% Next Q

Q2 (-2Q)

Grade C$77.58+4.3% Next Q

Q3 (-1Q)

Grade C$80.90+0.4% Next Q

Current

Grade C-$81.25+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LIVN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, LIVN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 65.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($78.49) or 200D SMA ($72.90) invalidates the momentum regime and cuts Target Base ($82.35) toward Bear Floor ($64.23).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LIVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LIVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

LIVN Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (LIVN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on LIVN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LIVN Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LIVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.19%⚡ TESTING RESISTANCE

2026-10-30O $81.38H $82.87L $78.41C $81.25VOL 575.6K

RES: $81.89SUP: $74.07SMA50: $78.49SMA200: $72.90

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LIVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LIVN Butterfly Map → + Track LIVN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

13.0%/yr Implied 5Y Growth

vs. +10.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LIVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LIVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LIVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LIVN)

Health Care Rank #179 of 1016 ⚔️ ITGR vs LIVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LIVN vs. ITGR, AXGN, TMDX, CNMD)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LivaNova PLC (LIVN) ranks #179 by composite RQD confidence (61/100, grade C-) and #171 by equity capitalization ($4.48B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. TMDX currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with LIVN at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LIVN ACTIVE LivaNova PLC	C-	61/100	—	67.7%	17.3%	+0.73%	$4.48B	Benchmark Subject
ITGR Integer Holdings Corporation	C+	67/100	41.8x	27.0%	6.0%	-0.02%	$4.30B	/itgr-vs-livn →
AXGN Axogen Inc.	D+	54/100	—	74.3%	-2.6%	+0.77%	$2.96B	/axgn-vs-livn →
TMDX TransMedics Group Inc.	C+	69/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	/tmdx-vs-livn →
CNMD CONMED Corporation	C	62/100	28.9x	54.6%	7.8%	-0.09%	$1.36B	/cnmd-vs-livn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001639691

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LivaNova PLC (LIVN) reported GAAP revenue of $1.39B (+10.7% vs. FY2024 revenue of $1.25B , and +20.3% cumulative change since FY2023) , GAAP net income of -$242.5M, operating cash flow of $254.3M, and free cash flow of $173.3M (+27.5% YoY). On the balance sheet, LIVN closed FY2025 with $2.61B in total assets against $345.2M in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.39B	-$242.5M	$254.3M	$173.3M	$2.61B	$345.2M
FY2024 (FY)	2024-12-31	$1.25B	$63.2M	$183.0M	$135.9M	$2.51B	$549.6M
FY2023 (FY)	2023-12-31	$1.15B	$17.6M	$74.9M	$74.9M	—	—

3. LIVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LIVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LIVN compare to ITGR and AXGN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LIVN?

Where is LIVN trading relative to its 50-day, 200-day, and 52-week technical levels?

LIVN last traded at $81.25 (+0.73% on volume of 483,339 shares), positioning the stock +3.52% above its 50-day simple moving average ($78.49) and +11.45% above its 200-day simple moving average ($72.90). Across its 52-week range of $48.82 to $85.76, LIVN sits at the 87.8% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($76.29 to $86.21).

LIVN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are LIVN insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies LIVN leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: LIVN RQD Cockpit LIVN 12M Forecast LIVN Earnings & Move LIVN Dividends & DRIP LIVN Insiders & 13F LIVN Whale Options LIVN Profit Sankey LIVN News & Why